Related Experiment Video
Updated: Jan 20, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Impact of intrafraction prostate motion on clinical target coverage in proton therapy: A simulation study of
Zhong Su1, Roelf Slopsema1, Stella Flampouri1
1Department of Radiation Oncology, University of Florida, and University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
Purpose:
To investigate the dosimetric impact of prostate intrafraction motion on proton double-scattering (DS) and uniform scanning (US) treatments using electromagnetic transponder-based prostate tracking data in simulated treatment deliveries.
Methods:
In proton DS delivery, the spread-out Bragg peak (SOBP) is created almost instantaneously by the constant rotation of the range modulator. US, however, delivers each entire energy layer of the SOBP sequentially from distal to proximal direction in time, which can interplay with prostate intrafraction motion. This spatiotemporal interplay during proton treatment was simulated to evaluate its dosimetric impact. Prostate clinical target volume (CTV) dose was obtained by moving CTV through dose matrices of the energy layers according to prostate-motion traces. Fourteen prostate intrafraction motion traces of each of 17 prostate patients were used in the simulated treatment deliveries. Both single fraction dose-volume histograms (DVHs) and fraction-cumulative DVHs were obtained for both 2 Gy per fraction and 7.25 Gy per fraction stereotactic body radiotherapy (SBRT).
Results:
The simulation results indicated that CTV dose degradation depends on the magnitude and direction of prostate intrafraction motion and is patient specific. For some individual fractions, prescription dose coverage decreased in both US and DS treatments, and hot and cold spots inside the CTV were observed in the US results. However, fraction-cumulative CTV dose coverage showed much reduced dose degradation for both DS and US treatments for both 2 Gy per fraction and SBRT simulations.
Conclusions:
This study indicated that CTV dose inhomogeneity may exist for some patients with severe prostate intrafraction motion during US treatments. However, there are no statistically significant dose differences between DS and US treatment simulations. Cumulative dose of multiple-fractions significantly reduced dose uncertainties.
Related Concept Videos
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
06:27Simulating Impacts of Ice Storms on Forest Ecosystems
09:11Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
06:21Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
07:01Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
11:29miRNA Expression Analyses in Prostate Cancer Clinical Tissues

